{"id":"early-dual-iv-antibiotic-therapy-mrsa","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This clinical protocol uses two synergistic IV antibiotics (typically vancomycin and a beta-lactam or fluoroquinolone) administered early in suspected or confirmed MRSA infection to achieve rapid bacterial killing and reduce resistance development. The dual approach targets different bacterial cell wall or protein synthesis pathways, improving clinical outcomes compared to monotherapy in severe MRSA infections.","oneSentence":"Early dual IV antibiotic therapy combines two intravenous antibiotics to simultaneously target methicillin-resistant Staphylococcus aureus (MRSA) through complementary bactericidal mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:36:10.536Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infection, severe or invasive"}]},"trialDetails":[{"nctId":"NCT03012360","phase":"PHASE4","title":"Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2018-02-08","conditions":"Mechanical Ventilation Complication, Critical Illness","enrollment":103},{"nctId":"NCT07148960","phase":"PHASE4","title":"Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?","status":"ENROLLING_BY_INVITATION","sponsor":"West Virginia University","startDate":"2025-09-15","conditions":"Staphylococcus Aureus Bacteremia","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["daptomycin","ceftaroline","rifampin"],"phase":"marketed","status":"active","brandName":"Early Dual IV Antibiotic Therapy - MRSA","genericName":"Early Dual IV Antibiotic Therapy - MRSA","companyName":"West Virginia University","companyId":"west-virginia-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Early dual IV antibiotic therapy combines two intravenous antibiotics to simultaneously target methicillin-resistant Staphylococcus aureus (MRSA) through complementary bactericidal mechanisms. Used for Methicillin-resistant Staphylococcus aureus (MRSA) infection, severe or invasive.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}